CXCR2 and chronic obstructive pulmonary disease: Previous studies indicated that CXC chemokine receptor 2 (CXCR2) antagonists can reduce neutrophils in the lungs of patients with COPD and thus can limit the harmful effects of neutrophils on the lung tissue [30].